[(2E)-6-oxocyclooct-2-en-1-yl] N-methylcarbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: [(2E)-6-oxocyclooct-2-en-1-yl] N-methylcarbamate
• 化学式: C₁₀H₁₅NO₃
• 分子量: 197.23
• InChiKey: QFHOOLRTKICXEQ-HWKANZROSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• BIO-ORTHOGONAL DRUG ACTIVATION
  申请人：KONINKLIJKE PHILIPS N.V.

  公开号：US20160106859A1

  公开（公告）日：2016-04-21

  The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.

  该发明涉及一种用于治疗学的原药激活方法，其中使用了表现出彼此生物正交反应性的非生物活性化学基团。该发明还涉及一种包含至少一种原药和至少一种激活剂的试剂盒，其中原药包含药物和第一个生物正交反应基团（触发器），而激活剂包含第二个生物正交反应基团。该发明还涉及在上述方法和试剂盒中使用的靶向治疗剂。该发明特别适用于抗体药物偶联物和双特异性及三特异性抗体衍生物。
• [EN] CHANNEL PROTEIN ACTIVATABLE LIPOSOMES<br/>[FR] LIPOSOMES ACTIVABLES PAR DES PROTÉINES DE CANAL
  申请人：TAGWORKS PHARMACEUTICALS B V

  公开号：WO2014081300A1

  公开（公告）日：2014-05-30

  Disclosed is a liposome, comprising a lipid bilayer enclosing a cavity, wherein the bilayer comprises a channel protein releasably linked to an eight-membered non-aromatic cyclic alkenylene group, preferably a cyclooctene group, and more preferably a trans-cyclooctene group. The liposomes are used in a kit comprising the liposome, the liposomal membrane of which comprises a channel protein linked to a Trigger, and an Activator for the Trigger, wherein the Trigger comprises the eight- membered non-aromatic cyclic alkenylene group, and the Activator comprises a diene.

  揭示了一种脂质体，包括包裹腔的脂质双层，其中双层包括与八元非芳香环烯链基（优选为环辛烯基，更优选为反式环辛烯基）可释放地连接的通道蛋白。这些脂质体用于一种套装，包括该脂质体，其脂质体膜包括连接到触发器的通道蛋白，以及用于触发器的激活剂，其中触发器包括八元非芳香环烯链基，而激活剂包括二烯。
• [EN] ACTIVATABLE LIPOSOMES<br/>[FR] LIPOSOME POUVANT ÊTRE ACTIF
  申请人：TAGWORKS PHARMACEUTICALS B V

  公开号：WO2014081299A1

  公开（公告）日：2014-05-30

  Disclosed are reactive liposome, comprising a lipid bilayer enclosing a cavity, wherein the bilayer comprises a linkage to an eight-membered non-aromatic cyclic alkenylene group, preferably a cyclooctene group, and more preferably a trans-cyclooctene group. The liposomes are use in a kit comprising the liposome linked, directly or indirectly, to a Trigger, and an Activator for the Trigger, wherein the Trigger comprises an eight-membered non-aromatic cyclic alkenylene group, and the Activator comprises a diene.

  揭示了一种反应性脂质体，包括一个脂质双层包裹的腔隙，其中该双层包括与一个含有八个成员的非芳香环烯基基团连接的连接，最好是环辛烯基团，更好是反式环辛烯基团。这些脂质体用于一种工具包，该工具包包括直接或间接地与一个触发器连接的脂质体，以及用于触发器的活化剂，其中触发器包括一个含有八个成员的非芳香环烯基基团，而活化剂包括一个二烯。
• [EN] TETRAZINES FOR HIGH CLICK RELEASE SPEED AND YIELD<br/>[FR] TÉTRAZINES POUR UNE VITESSE ET UN RENDEMENT DE LIBÉRATION DE CHIMIE CLIC ÉLEVÉS
  申请人：TAGWORKS PHARMACEUTICALS B V

  公开号：WO2020256544A1

  公开（公告）日：2020-12-24

  Disclosed herein are tetrazines substituted with groups that result in a high click conjugation yield and high click release yields. In some of several other aspects, the invention relates to combinations and kits comprising said tetrazines and a dienophile, preferably a trans-cyclooctene. In another aspect, the compounds, combinations, and kits are for use as a medicament.

  本文揭示了用于高点击共轭产量和高点击释放产量的基团替代的四唑类化合物。在其他几个方面，本发明涉及包括所述四唑类化合物和双亲核烯的组合和试剂盒，其中双亲核烯优选为反-环辛烯。在另一个方面，这些化合物、组合和试剂盒可用作药物。
• [EN] AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO<br/>[FR] AGENTS PERMETTANT DE CLIVER IN VIVO DES MARQUEURS LIÉS À DES BIOMOLÉCULES
  申请人：TAGWORKS PHARMACEUTICALS B V

  公开号：WO2020256545A1

  公开（公告）日：2020-12-24

  Disclosed herein are compounds comprising trans-cyclooctene moieties, combinations, and kits that can be used to more quickly remove radionuclides from a subject, preferably a human being. Said compounds, combinations and kits can also be used to increase the tumor-to-blood ratio, or to more rapidly and/or conveniently achieve such an increase, of a label in targeted imaging or targeted radiotherapy in a subject, preferably a human being.

  本文所披露的化合物包括顺-环辛烯基团，组合物和套装，可用于更快地从受试者（最好是人）中清除放射性核素。所述化合物、组合物和套装还可用于增加靶向成像或靶向放射治疗中标记物的肿瘤/血液比率，或更快地和/或更方便地实现这种增加，适用于受试者（最好是人）。